Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer - Wikidata - wikimedia - TriplyDB

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

http://www.wikidata.org/entity/Q35079955

about

Epigenetic polypharmacology: from combination therapy to multitargeted drugs Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases.Histones: Controlling Tumor Signaling Circuitry Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression RNA polymerase II pausing can be retained or acquired during activation of genes involved in the epithelial to mesenchymal transition.Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.Targeting Histone Deacetylases in Diseases: Where Are We?The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells.Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo.HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.The epigenome as a potential mediator of cancer and disease prevention in prenatal development.The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.Histone deacetylase regulation of ATM-mediated DNA damage signaling.Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells.Sensitization strategies in lung cancer Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer Histone deacetylase inhibitors in the generation of the anti-tumour immune response.Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.Multiple roles of class I HDACs in proliferation, differentiation, and development.The bromodomain interaction module.Targeting class I histone deacetylases in cancer therapy.Long-range transcriptional regulation of breast cancer genes.Targeting homologous recombination-mediated DNA repair in cancer.

P2860

Q28067666-A3204583-A7CE-4446-8AF9-EF76CF14CEF1 Q28073020-85A5B9DB-A637-4F8B-9D93-B8257FE57945 Q30303153-D11D1A1F-C0DC-462F-ABFC-467417C8932A Q33430193-4D8A3E41-2992-4408-ADB8-45AD9AF94545 Q33437309-B7481120-DA72-433E-9830-4764B87A77EB Q33635942-1CBF8227-68D9-42FD-B12F-07A44F11623C Q34109472-FD0D6F2A-62BB-4AA4-8FC3-F310E1A9305E Q34618963-5B93F9D7-7F15-4C3E-B824-58A596B4361F Q34662212-F5BD4E30-825E-4423-B02E-34096DC1BCAA Q34693969-CCBD77E7-3504-417A-8657-967845867C34 Q35044051-D84E08F1-88D9-4880-90CA-B21F27E87BBE Q35178901-3280018C-5E45-467F-9F34-2B5342EC29E7 Q35201384-1CB6F761-123F-466E-AF6D-4B78E95E8268 Q35562114-54109545-F8AD-47C1-A9FD-71F82FEC7004 Q35653852-338F07BD-9A8D-4815-A10C-6F83A18F0DCA Q35821728-AF7C5429-8C5A-4E2A-B972-FFD51CD726D3 Q35890561-75DCAF4F-1F70-4885-8A61-BAE58D97A032 Q36224948-9276C517-8008-466B-800A-6E2748A0BE72 Q36282754-A289349F-E901-4338-8790-FFEE13E9D810 Q36290436-99DB1EB3-EC0B-4CDB-B7C6-600D8021F39C Q36517999-11C368A7-C6E2-421C-807F-34C86809C92B Q36545233-1847970F-1900-4460-AB41-35CA79EE3726 Q36546534-48741B65-5246-4B7F-9224-20DD7711C025 Q36694288-2A711FB3-8820-4CA1-8FFC-5B9BBB11349B Q36729432-0A99906D-E030-4A03-B9BE-9738D25EE93A Q36990438-F344E756-EE9C-4D20-A61A-550DC75DCF46 Q37212017-C41109A1-9550-4C63-9D9D-366B22BB7E2C Q37291739-4FFEAF86-4A73-42B1-9135-E5D2FC4BD795 Q37297635-6F74B98D-7FB4-4D2D-A8E2-839A0D9B8F52 Q37368670-AF4289A4-92F1-40BD-9214-B29BF448FEDF Q37407122-A4DC2BE3-9425-4DFA-A81D-80F49395E58A Q37413127-1FEFABE2-8B40-438D-8DFC-76A12CD20D01 Q37592666-C96BF38A-E611-41D8-A5C9-46454360F314 Q37953826-6C9D6326-429B-47C4-AF51-F7AB44582764 Q37962586-8EC47C04-7F28-4F02-83AB-5AF91A59E815 Q37979639-CDAF6429-ED33-4583-ABBC-E6E837498DAE Q38019699-131A7F0C-AA90-4F89-94B0-B24795C62D03 Q38051736-F04A3981-4DF8-4FE7-8EAB-262EF23F1AB6 Q38053130-41154498-CD04-48B3-9265-2A5890E1594D Q38184667-0AA5047A-F9C7-4AFE-B708-3718F0857808

P2860

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

http://www.wikidata.org/entity/Q35079955

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Rational therapeutic combinati ...... rs for the treatment of cancer

@ast

Rational therapeutic combinati ...... rs for the treatment of cancer

@en

type

label

Rational therapeutic combinati ...... rs for the treatment of cancer

@ast

Rational therapeutic combinati ...... rs for the treatment of cancer

@en

prefLabel

Rational therapeutic combinati ...... rs for the treatment of cancer

@ast

Rational therapeutic combinati ...... rs for the treatment of cancer

@en

P1433

Q35079955-9AD95FC2-052B-4C20-98A8-4DAF9C025E42

P1476

Q35079955-459DEC73-5527-4C03-AE7A-E5612C576DC9

P2093

Q35079955-4C19F3F3-307F-4295-A060-D2E91C602F10

Q35079955-A1CE5F74-32D0-4152-B5CF-B0E3F2D8A515

Q35079955-B61BB81C-36AB-4BA0-A381-3729C0D28AAB

Q35079955-F98FB08B-C331-4978-9772-8EFFD2BB1252

P2860

Q35079955-005293B5-C348-4AB0-A576-4E27F801FC49

Q35079955-0230D0A3-C43B-41F2-91C7-05D6519A123C

Q35079955-026EF50C-3682-40C9-B6DA-EF07BB39FC73

Q35079955-0482FBDD-0F01-46EF-957E-48DD61830943

Q35079955-05CE1437-307A-458A-9321-AF8E3183476E

Q35079955-05E96DE3-FD9A-49E6-83CF-27A362C879D1

Q35079955-06ADE9D7-65E8-4709-9BB9-819881BC4A7A

Q35079955-06DD1135-24BB-4F4B-A562-56A5F8F2D1AA

Q35079955-084F9B13-DC6A-4AF4-B5D8-8216F0AD07B0

Q35079955-08B6CF58-3EF0-435C-B899-B5BA688DF351

P304

Q35079955-914D0FC9-6542-4E98-AB75-866892E89352

P31

Q35079955-AA06715B-CC20-4335-8D84-7C145FAFAC4A

P356

Q35079955-B32FC9A3-4C74-4D5E-B115-ED1E9E8EBD00

P407

Q35079955-BB546966-A165-4ECE-A26B-4545A05A0548

P433

Q35079955-8668C7DA-7065-4964-92E6-FA9B3EDB80BC

P478

Q35079955-D7327CB0-12CD-4D7D-A31E-47FD9888E756

P577

Q35079955-654194E3-793B-4302-A589-E3606E26C0C4

P5875

Q35079955-1622B9D2-7F5F-4090-9179-B3E3D15BB4BA

P698

Q35079955-12C5B53D-E900-4990-BB0C-8E2EA78EE743

P932

Q35079955-E45FB7E6-F4D1-4CDC-A192-9F484EEE6804

P356

P1433

Future Oncology

P1476

Rational therapeutic combinati ...... rs for the treatment of cancer

@en

P2093

Amy Moore

http://www.w3.org/2001/XMLSchema#string

K Ted Thurn

http://www.w3.org/2001/XMLSchema#string

Pamela N Munster

http://www.w3.org/2001/XMLSchema#string

Scott Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

DNA methylation patterns and epigenetic memory

Histone deacetylases specifically down-regulate p53-dependent gene activation

Histone deacetylase interacts directly with DNA topoisomerase II

Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis

HDAC6 is a microtubule-associated deacetylase

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability

Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling

MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Targeting DNA topoisomerase II in cancer chemotherapy

P304

263-283

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.11.2

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49942547

http://www.w3.org/2001/XMLSchema#string

P698

21345145

http://www.w3.org/2001/XMLSchema#string

P932

3127396

http://www.w3.org/2001/XMLSchema#string